Current therapies for the treatment of T2D are focused on normalizing blood glucose either by increasing insulin secretion in existing pancreatic β-cells or by improving insulin sensitivity and reducing complications [5]. The gene discussed is INS; the disease is type 2 diabetes mellitus.